# ARPA-H BioStabilization Systems program

> Live situation record from CLSTR: https://clstr.news/situations/arpa-h-biostabilization-systems-program
> Updated: 2026-10-08T18:37:52.000Z. Sources: 4. Developments: 2.

The Advanced Research Projects Agency for Health (ARPA-H) has launched the BioStabilization Systems (BoSS) program, committing up to $87 million over four years. The initiative focuses on developing technologies for the production, storage, and transport of cell-based biologic medicines at room temperature to reduce reliance on expensive cold-chain logistics.

As part of the Phase I funding round, the Reversible Ambient Biostabilization (RAB) team, led by Likarda and managed by Draper, was awarded up to $7.3 million. The multidisciplinary team includes CaseBioscience, CPSI Biotech, Fresenius Kabi, MiNK Therapeutics, and the University of Colorado Boulder. The RAB team intends to use AI-assisted design and freeze-assisted droplet drying to optimize cell stability, aiming to make biological medicines as easy to ship and store as aspirin.

## Timeline

### 2026-10-08: ARPA-H funds program to stabilize cell therapies at room temperature

ARPA-H is investing up to $87 million into its BoSS program to develop room-temperature storage and transport solutions for cell-based therapies and biologics.

2 sources. https://clstr.news/cluster/arpa-h-funds-program-to-stabilize-cell-therapies-at-room-temperature

### 2026-10-01: ARPA-H awards $7.3 million to team including CaseBioscience

CaseBioscience joined a Likarda-led team awarded $7.3 million by ARPA-H to develop room-temperature storage and transport methods for cell therapies, aiming to reduce cold-chain logistics dependency.

2 sources. https://clstr.news/cluster/arpa-h-awards-73-million-to-team-including-casebioscience

---
Cite as: ARPA-H BioStabilization Systems program. CLSTR, https://clstr.news/situations/arpa-h-biostabilization-systems-program